2. UroToday Home
  3. Video Lectures

Advanced Kidney Cancer

Five Things Urologists Need to Know About Bladder and Kidney Cancer in 2025 "Presentation" - Gautam Jayram
November 19, 2024
Details
Research Maps Renal Cancer Transcription Signatures - Pedro Barata
November 7, 2024
Details
Innovative Therapies in GU Cancers: Promising Targets in Urothelial and Kidney Cancer - Jonathan Rosenberg
November 7, 2024
Details
CheckMate 67T: Subcutaneous Nivolumab Non-Inferior to Intravenous in Advanced RCC - Laurence Albiges
November 1, 2024
Details
Belzutifan vs Everolimus Trial Data in Advanced RCC Care - Brian Rini
October 30, 2024
Details
Oligometastatic vs Oligoprogressive RCC Treatment Strategies - Chad Tang
October 7, 2024
Details
Highlights in Non-Prostate GU Oncology from ESMO 2024 - Ignacio Duran
October 4, 2024
Details
Glycoproteomics in Kidney Cancer: CheckMate 9ER Biomarker Analysis - David Braun
September 23, 2024
Details
CaboPoint Trial: Cabozantinib in Second-Line RCC Treatment - Laurence Albiges
September 19, 2024
Details
Fecal Microbiota Transplant Boosts Immunotherapy in Metastatic Renal Cell Carcinoma in TACITO-II Trial - Chiara Ciccarese
September 15, 2024
Details
HIF-2 Alpha Inhibitor NKT2152 Shows Impact in Renal Cell Carcinoma - Eric Jonasch
September 13, 2024
Details
TiNivo-2 Trial Results in Advanced Renal Cell Carcinoma Treatment - Toni Choueiri
September 13, 2024
Details
Prognostic Significance of Absolute Lymphocyte Count in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Combination Immunotherapies - Database Consortium - Beyond the Abstract
July 18, 2024
Details
Durvalumab Plus Guadecitabine in Metastatic Kidney Cancer: Phase 1/2 Trial Results - Yousef Zakharia
July 5, 2024
Details
Advancements in Cutting-Edge SABR Therapy for Oligometastatic Kidney Cancer - Shankar Siva
April 11, 2024
Details
CheckMate-67T: Subcutaneous Nivolumab Shows Comparable Results to IV, Reduces Treatment Burden in RCC - Saby George
March 5, 2024
Details
CheckMate-214 at 8 Years: Nivolumab + Ipilimumab Shows Durable Survival Benefit in Advanced RCC - Nizar Tannir
March 5, 2024
Details
The Role of Nephrectomy with Immunotherapy in Metastatic Renal Cell Carcinoma - Dimitrios Makrakis
February 29, 2024
Details
Cabozantinib and Nivolumab Combination Therapy Shows Durable Efficacy in Advanced Kidney Cancer - María Bourlon
February 29, 2024
Details
Bispecific Antibody Inhibiting PD-1 and CTLA-4 Demonstrates Effectiveness Against Advanced Kidney Cancer in Early Study - Martin Voss
November 22, 2023
Details
Targeted Kidney Cancer Therapy Sparks Hope For Tough-To-Treat Patients - Dan George
November 16, 2023
Details
The LITESPARK-013 Trial and Belzutifan's Optimal Dose for Treating Metastatic Renal Cell Carcinoma - Neeraj Agarwal
November 10, 2023
Details
A Conversation on AXL Inhibition in Advanced RCC: Promising Results from a Phase I/IIb Trial - Kathryn Beckermann
July 31, 2023
Details
Breaking Down Genomic Data: An In-depth Look at Ancestry and Tumor Biology in Kidney Cancer - Ritesh Kotecha
July 11, 2023
Details
KEYNOTE-B61 Study Reveals Promising Results of Lenvatinib + Pembrolizumab Combo in Non-Clear Cell RCC - Chung-Han Lee
July 10, 2023
Details
Exploring the Link between Gut Microbiome and Immunotherapy Response in Metastatic Renal Cell Carcinoma - Nazli Dizman
July 7, 2023
Details
Exploring Cytoreductive Nephrectomy in Metastatic Sarcomatoid or Rhabdoid RCC - Andrew Hahn
July 7, 2023
Details
Interpreting the Outcomes of a Non-Inferiority Phase II Trial: Comparing Lenvatinib Dosages and Their Impact on the Quality of Life in Renal Cell Carcinoma Patients - Cristiane Bergerot
July 7, 2023
Details
Impact of Subsequent Therapies in Patients with aRCC Receiving Lenvatinib plus Pembrolizumab or Sunitinib in the CLEAR Study - Martin Voss
July 6, 2023
Details
A Conversation on Changing Trends in Advanced RCC Treatment: An Analysis of Real-World Data - Neil Shah
July 6, 2023
Details
Artificial Intelligence Modelling to Predict the Risk of Cardiotoxicity Among Renal Cell Carcinoma Patients - Hesham Yasin
July 5, 2023
Details
Long-Term Progression Free Survival from TIVO-3: Tivozanib vs Sorafenib in Relapsed/refractory Advanced RCC - Michael Atkins
June 30, 2023
Details
Efficacy of Lenvatinib + Pembrolizumab Versus Sunitinib in Patients with Advanced Renal Cell Carcinoma in the CLEAR Trial - Camillo Porta
June 28, 2023
Details
Activity of Tivozanib in Non-Clear Cell Renal Cell Carcinoma - Pedro C. Barata
June 28, 2023
Details
Maturation of Overall Survival in TIVO-3 with Long-Term Follow-Up - Kathryn Beckermann
June 28, 2023
Details
Phase 2 Study of Neoadjuvant Cabozantinib in Patients with Localized Advanced Non-Metastatic ccRCC - Mehmet Asim Bilen
June 27, 2023
Details
The SAMURAI Study's Role in Evolving Radiation Therapy for Kidney Cancer - Rana McKay & William Hall
June 27, 2023
Details
Progression-Free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-Line Immunotherapy Combinations - Kelly Fitzgerald
June 27, 2023
Details
From Trial to Treatment: Exploring the Lasting Impact of KEYNOTE-426 in Kidney Cancer - Brian Rini
June 20, 2023
Details
Efficacy over Cost: Unpacking Kidney Cancer Patients' Therapy Selection Priorities - Dena Battle
June 15, 2023
Details
Deciphering Immunotherapy Responses in Advanced RCC: A Deep Dive into the HCRN Study - Nourhan El Ahmar
June 15, 2023
Details
Treatment of Recurrent Metastatic Renal Cell Carcinoma After Adjuvant Immunotherapy - Benjamin Berger & Matthew Labriola
June 12, 2023
Details
Unraveling the Efficacy of PD-1/PDL-1 Re-challenge in Kidney Cancer: CONTACT-03 Study - Toni K. Choueiri
June 2, 2023
Details
COSMIC-313: Investigating Progression-Free Survival Benefits in Renal Cancer Therapy - Toni K. Choueiri
June 2, 2023
Details
Combining Belzutifan Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma, Exploring Novel Therapy Options - Toni Choueiri
May 15, 2023
Details
Comparing the Cost-Effectiveness of Immunotherapy-Based Regimens and Sunitinib in Treating Metastatic Renal Cell Carcinoma from a Public Payer Perspective - Manish Kohli
April 10, 2023
Details
Overall Survival and Efficacy Results of Second-line Treatment for Patients With Metastatic Clear Cell Renal Cell Carcinoma, BIONIKK Trial -Yann Vano
March 23, 2023
Details
3-Year Follow-up CheckMate 9ER Trial: Nivolumab plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma - Mauricio Burotto
March 21, 2023
Details
CaboPoint Study: Cabozantinib After Checkpoint Inhibitor Therapy in Patients with Advanced Renal Cell Carcinoma - Laurence Albiges
March 20, 2023
Details
Cabozantinib in Combination with Atezolizumab in Non-Clear Cell Renal Cell Carcinoma: Extended Follow-up Results of Cohort 10 of the COSMIC-021 Study - Bradley McGregor
March 20, 2023
Details
The Evolving Field of Kidney Cancer Treatment: The COSMIC-313 Trial and Beyond - Thomas Powles
March 14, 2023
Details
HCRN GU 16-260, Nivolumab and Salvage Nivolumab+Ipilimumab in Patients with Advanced Renal Cell Carcinoma Cohort A, Treatment-Free Survival Outcomes - Michael Atkins
February 22, 2023
Details
Promising Depth of Response Data in Renal Cell Carcinoma: Insights from CheckMate 9ER Trial - Cristina Suárez
January 31, 2023
Details
BIONIKK Trial: Pioneering Biomarker-Driven Therapy for Advanced Clear Cell RCC - Yann-Alexandre Vano
January 30, 2023
Details
The CLEAR Study: Lenvatinib + Pembro vs Sunitinib in Advanced RCC - Camillo Porta
January 25, 2023
Details
PIVOT-09 Trial: An In-Depth Analysis of Revisiting IL-2 Therapies in Advanced RCC - Nizar Tannir
January 25, 2023
Details
The Association Between Depth of Response and Clinical Outcomes in the CheckMate 9ER Trial in Advanced Renal Cell Carcinoma - Andrea Apolo
January 19, 2023
Details
Innovations and Advances in Advanced Kidney Cancer - Toni Choueiri
January 18, 2023
Details
Durvalumab Alone or with Savolitinib or Tremelimumab in Previously Treated Advanced Clear Cell Renal Cancer - CALYPSO Trial Results - Tom Powles
January 4, 2023
Details
The ORACLE Study: The Efficacy of Combination Systemic Therapies in Patients with Non-Clear Cell Renal Cell Carcinoma - Deepak Kilari
January 3, 2023
Details
Advancing Therapeutic Approaches in Sarcomatoid Renal Cell Carcinoma: Lessons from CheckMate 214 - Nizar Tannir
December 19, 2022
Details
Results from a Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma - Hans Hammers
December 16, 2022
Details
The CANTATA Trial - Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced RCC - Nizar Tannir
December 9, 2022
Details
CheckMate 9ER: Extended Follow-Up Reveals Long-Term Benefits of Cabozantinib-Nivolumab Combo for Advanced Renal Cell Carcinoma - Toni Choueiri
December 7, 2022
Details
Predicting Efficacy of Both Nivolumab and of Nivolumab + Ipilimumab in Frontline mccRCC Patients, An Ancillary Analyses from the BIONIKK Randomized Trial - Maxime Meylan
December 6, 2022
Details
Exploring the PROSPER Study: A Neoadjuvant Approach to Kidney Cancer - Mohamad Allaf
November 17, 2022
Details
The PROSPER Trial: A Comprehensive Analysis of Neoadjuvant Nivolumab in Renal Cancer - Naomi Haas
November 2, 2022
Details
Results of a Phase II Randomized Double Blind Trial of PF-04518600, OX40 Antibody, in Combination with Axitinib - Sarmad Sadeghi
October 17, 2022
Details
Clinical Trial Endpoints in the Adjuvant Setting for Renal Cell Carcinoma and Urothelial Cancer - Andrea Apolo and Pavlos Msaouel
October 16, 2022
Details
Belzutifan Plus Cabozantinib Shows Manageable Safety with Promising Antitumor Activity In Treatment-Naïve Advanced Clear Cell RCC, The LITESPARK-003 Study - Toni K. Choueiri
October 16, 2022
Details
Triplet Therapy With Cabozantinib, Nivolumab, and Ipilimumab as First-line Treatment in Patients With Advanced Renal Cell Carcinoma, COSMIC 313 - Toni K. Choueiri
October 3, 2022
Details
Adding Fecal Microbiota Transplantation (FMT) in Combination with Immunotherapy to Treat Renal Cell Carcinoma, The PERFORM Study - Ricardo Fernandes
September 26, 2022
Details
OMNIVORE - Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma, Journal Club - Christopher Wallis & Zachary Klaassen
September 25, 2022
Details
Final Results of TITAN-RCC Trial - Is a Tailored Approach of Nivolumab and Nivolumab/Ipilimumab as Immunotherapeutic Boost Recommended - Marc-Oliver Grimm
September 22, 2022
Details
Is There Still a Role for Cytoreductive Nephrectomy? Analysis from the CARMENA Trial, Journal Club - Christopher Wallis & Zachary Klaassen
August 30, 2022
Details
CheckMate 214: A Deep Dive into Ipilimumab and Nivolumab for Advanced Renal Cell Carcinoma - David Cella
August 16, 2022
Details
The First Neoadjuvant Trial Using Combination Immune Checkpoint Inhibitor and VEGF Inhibitor in Patients With Locally Advanced High-Risk RCC (NeoAvAx) – Axel Bex
May 24, 2022
Details
The Upcoming 2022 European International Kidney Cancer Symposium - Samra Turajlic
April 12, 2022
Details
KEYNOTE-564 30-Month Follow-Up of Pembrolizumab as Post Nephrectomy Adjuvant Therapy for Patients with Renal Cell Carcinoma - Toni Choueiri
March 4, 2022
Details
42-Month Follow-up of KEYNOTE-426, Pembrolizumab plus Axitinib First-Line Treatment for Advanced Renal Cell Carcinoma - Thomas Powles
August 18, 2021
Details
Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma, The CLEAR Trial Journal Club - Christopher Wallis & Zachary Klaassen
August 12, 2021
Details
VEGF Blockade and Combination Therapeutic Options in Advanced Renal Cell Carcinoma - Andrea Apolo
July 8, 2021
Details
ESMO 2020: CheckMate-9ER Study of Nivolumab Combined With Cabozantinib Vs. Sunitinib in Participants With Previously Untreated mRCC - Toni Choueiri
September 28, 2020
Details
Safety and Efficacy of CDX-014, an Antibody-drug Conjugate Directed Against T cell Immunoglobulin Mucin-1 in Advanced Renal Cell Carcinoma - Bradley McGregor
July 29, 2020
Details
Combination Therapies in Metastatic Kidney Cancer - Chung-Han (Joe) Lee
July 7, 2020
Details
Advanced Renal Cell Carcinoma Clinical Research Outcomes and Clinical Implications from ASCO 2020 - Toni Choueiri
June 14, 2020
Details
Immunogenomic Characterization of Advanced Clear Cell Renal Cell Carcinoma Treated with PD-1 Blockade - David Braun
May 30, 2020
Details
OMNIVORE: Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma - Rana McKay
May 30, 2020
Details
KEYNOTE-426: Pembrolizumab plus Axitinib versus Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma (RCC) - Brian Rini
May 28, 2020
Details
Frontline Treatment in Advanced Kidney Cancer - Bradley McGregor
March 17, 2020
Details
Atezolizumab and Bevacizumab in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma - Rana Mckay
March 12, 2019
Details
Clinical Trials in Non-clear Cell Kidney Cancer - Darren Feldman
January 15, 2020
Details
Targeted Therapeutic Approaches to Treat Advanced Kidney Cancer - Che-Kai Tsao
January 15, 2020
Details
The Use of Active Surveillance in Metastatic Kidney Disease - Jaime Landman and Monty Pal
December 10, 2019
Details
First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic RCC Database Consortium - Shaan Dudani
October 11, 2019
Details
Innovative Research for Advanced Kidney Cancer - David Braun
August 17, 2019
Details
First-line Therapy Options for Metastatic Renal Cell Carcinoma - Tian Zhang
July 13, 2019
Details
The Landscape of Systemic Therapy for Metastatic Renal Cell Carcinoma - Petros Grivas
June 24, 2019
Details
The Dynamic Landscape of mRCC and the PDIGREE Trial - Tian Zhang
June 7, 2019
Details
Newly Approved Treatment Options for the Management of Metastatic Kidney Cancer- Lauren Harshman and Toni Choueiri
June 10, 2019
Details
Targeted Therapies with Immunotherapies In Kidney Cancer - Thomas Powles
April 21, 2019
Details
Rapidly Evolving Landscape in Metastatic Renal Cell Carcinoma- Rana McKay
May 25, 2019
Details
Frontline Data from Keynote 426 - Sandy Srinivas
May 25, 2019
Details
Paradigm Changing Data for Kidney Cancer - Primo Lara
May 24, 2019
Details
Patient Perspectives on Cytoreductive Nephrectomy after the CARMENA Trial - Dena Battle
February 26, 2019
Details
Patient Advocacy and Resources in Kidney Cancer - Dena Battle
February 6, 2019
Details
Monitoring Treatment Toxicities in Patients with Renal Cell Carcinoma: discussion with Dan George and Tian Zhang
November 29, 2018
Details
Evolution of the NCCN Guidelines for Kidney Cancer -Tian Zhang
November 19, 2018
Details
Systemic Therapy Options for Renal Cell Carcinoma - Monty Pal
November 8, 2018
Details
The Use of Molecular Profile in Renal Cancer - Martin Voss
November 6, 2018
Details
ASSET, A Pilot Study Using Exercise Physiology in Advanced Renal Cell Carcinoma - Mike Harrison
October 17, 2018
Details
A Review of Adjuvant Studies in Advanced Renal Cell Carcinoma - Tian Zhang
October 16, 2018
Details
CABOSUN Trial Plus an In-depth Discussion of Kidney Cancer Treatments - Toni Choueiri
October 8, 2018
Details
CARMENA: Practice Changing Strategies for Kidney Cancer
August 30, 2018
Details